Akero ex­ec­u­tives point to ad­vanced fi­bro­sis pa­tients for MASH drug

Last year
R&D
Pharma

Up­dat­ed: FDA ap­proves weight loss drug We­govy to re­duce car­dio­vas­cu­lar events

Last year
Pharma
FDA+

Gilead­'s on­col­o­gy cam­paign spot­lights metasta­t­ic breast can­cer pa­tients who of­ten feel un­seen

Last year
Pharma
Marketing

The FDA al­most nev­er pulls ful­ly-ap­proved drugs. Amy­lyx's ALS treat­ment might be the ex­cep­tion

Last year
R&D
FDA+

Up­dat­ed: Sam­sung Bio leans in­to ADC, gene ther­a­py is an ‘area of in­ter­est’

Last year
Manufacturing

In­ven­ti­va restarts PhI­II screen­ing for MASH tri­al; CD­MO an­nounces small pub­lic of­fer­ing

Last year
News Briefing

Macro­Gen­ics, Ab­b­Vie stop de­vel­op­ment of part­nered ADC

Last year
Deals
R&D

Amy­lyx's ALS treat­ment Re­lyvrio fails PhI­II study, biotech to con­sid­er with­draw­ing drug

Last year
R&D

Eye­Point poach­es med­ical chief from Apel­lis; San­doz CFO, long­time BioN­Tech ex­ec to re­tire

Last year
People
Peer Review

In sur­prise move, FDA de­lays de­ci­sion on Lil­ly’s Alzheimer’s drug, will con­vene ad­vi­so­ry com­mit­tee

Last year
FDA+

Kro­nos Bio cuts a fifth of staff, ex­plores new dos­ing sched­ule for sol­id tu­mor drug

Last year
People
R&D

David Bak­er's lab re­leas­es new pro­tein de­sign and study tools as AI race ac­cel­er­ates

Last year
R&D
AI

Up­dat­ed: Phar­ma com­pa­nies present IRA cas­es in New Jer­sey court

Last year
Pharma
Law

Law­mak­ers call for 'line in the sand' be­tween US and Chi­nese biotech com­pa­nies

Last year
China
Pharma

BeiGene’s Brukin­sa bags fifth FDA ap­proval, like­ly po­si­tion­ing it for con­tin­ued sales growth

Last year
Pharma
FDA+

Lil­ly push­es back on the pop cul­ture clam­or for obe­si­ty drugs in new TV ads

Last year
Pharma
Marketing

Boehringer In­gel­heim caps in­haler out-of-pock­et costs at $35 af­ter po­lit­i­cal pres­sure

Last year
Pharma

Bris­tol My­ers nabs ap­proval for Op­di­vo com­bo as first-line blad­der can­cer treat­ment

Last year
R&D
Pharma

No­vo un­like­ly to out­source API pro­duc­tion for GLP-1s but will stay en­gaged with fill-fin­ish part­ners

Last year
Manufacturing

Evonik lays off 2,000 staffers; Eu­rek­aBio gets $40M for vi­ral vec­tor pro­duc­tion; Sarep­ta un­fazed by No­vo-Catal­ent ...

Last year
Manufacturing

Up­dat­ed: Even with no pri­ma­ry end­point da­ta, Tau­Rx still eyes Alzheimer’s fil­ing af­ter PhI­II up­date

Last year
R&D

FO­MO, detox and depth: Why this biotech ral­ly may (fi­nal­ly) be re­al

Last year
Financing

Ul­ti­movac­s' melanoma vac­cine fails in PhII; Re­genxbio’s $140M of­fer­ing

Last year
News Briefing

No­vo touts ear­ly da­ta for next-gen oral weight loss drug as it out­lines next steps

Last year
R&D
Pharma
First page Previous page 188189190191192193194 Next page Last page
A service from the Financial Times